Celecoxib analogs that lack COX-2 inhibitory function: Preclinical development of novel anticancer drugs

Expert Opinion on Investigational Drugs

Volumn 17, Issue 2, 2008, Pages 197-208

  Schönthal, Axel H ^a   Chen, Thomas C ^b   Hofman, Florence M ^b   Louie, Stan G ^b   Petasis, Nicos A ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antitumor agent; Cardiovascular risk; Celecoxib; Chemoprevention; COX 2 inhibitor; Cyclooxygenase; ER stress; Rofecoxib; Valdecoxib

Indexed keywords

2, 5 DIMETHYLCELECOXIB; ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IMATINIB; IRINOTECAN; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSU 03012; OSU 03013; ROFECOXIB; TRASTUZUMAB; TT 101; UNCLASSIFIED DRUG; VALDECOXIB; 2,5 DIMETHYLCELECOXIB; 2,5-DIMETHYLCELECOXIB; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADENOMATOUS POLYP; ADJUVANT THERAPY; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTHRITIS; BRAIN TUMOR; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHRONIC PAIN; CLINICAL TRIAL; COLON CANCER; COLORECTAL ADENOMA; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; IC 50; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROSTATE ADENOCARCINOMA; REVIEW; RISK REDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY);

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PYRAZOLES; SULFONAMIDES;

EID: 39049101494     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.2.197     Document Type: Review

References (91)

1. Smith WL, Dewitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Ann Rev Biochem 2000;69:145-82
2. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002:94(4):252-66
3. Funk CD, Fitzgerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007;50(5):470-9
4. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332(7553):1302-8
5. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-44
6. Wallace JL, Devchand PR. Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol 2005;145(3):275-82
7. Crosby CG, Dubois RN. The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. Expert Opin Emerging Drugs 2003;8(1):1-7
8. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4(6):431-6
9. Masferrer JL. Cyclooxygenase-2 inhibitors in cancer prevention and treatment. Adv Exp Med Biol 2003;532:209-13
10. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6(2):130-40
11. Grösch S, Maier TJ, Schiffmann S, et al. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006;98(11):736-47
12. Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 2005;70(7):969-86
13. Di Fiore A, Pedone C, D'Ambrosio K, et al. Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib. Bioorg Med Chem Lett 2006;16(2):437-42
14. Knudsen JF, Carlsson U, Hammarstrom P, et al. The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II. Inflammation 2004;28(5):285-90
15. Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2004;47(3):550-7
16. Schönthal AH. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 2007;97(11):1465-8
17. Rigas B, Kashfi K. Cancer prevention: a new era beyond cyclooxygenase-2. J Pharmacol Exp Ther 2005;314(1):1-8
18. Zhu J, Song X, Lin HP, et al. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 2002;94(23):1745-57
19. Schönthal AH. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioblastoma therapy. Neurosurg Focus 2006;20(4):E21, 1-10
20. Gupta RA, Dubois RN. Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology 1998;114(5):1095-8
21. Zhang Y, Morham SG, Langenbach R, et al. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999;190(4):451-9
22. Raz A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 2002;63(3):343-7
23. Williams CS, Watson AJ, Sheng H, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000;60(21):6045-51
24. Pyrko P, Soriano N, Kardosh A, et al. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 2006;5(1):19
25. Kulp SK, Yang YT, Hung CC, et al. 3-Phosphoinositide-dependent protein kinase-1/Akt sign4ling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64(4):1444-51
26. Pyrko P, Kardosh A, Liu YT, et al. Calcium-activated ER stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib (DMC), a non-coxib analog of celecoxib. Mol Cancer Ther 2007;6(4):1262-75
27. Johnson AJ, Hsu AL, Lin HP, et al. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 2002;366(Pt 3):831-7
28. Alloza I, Baxter A, Chen Q, et al. Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum. Mol Pharmacol 2006;69(5):1579-87
29. Johnson AJ, Song X, Hsu A, et al. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 2001;41:221-35
30. Tanaka K, Tomisato W, Hoshino, T, et al. Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J Biol Chem 2005;280(35):31059-67
31. Kim SH, Hwang CI, Park WY, et al. GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. Carcinogenesis 2007;28(1):223-31
32. Tsutsumi S, Gotoh T, Tomisato W, et al. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ 2004;11(9):1009-16
33. Tsutsumi S, Namba T, Tanaka KI, et al. Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells. Oncogene 2006;25(7):1018-29
34. Pyrko P, Kardosh A, Schönthal AH. Celecoxib transiently inhibits protein synthesis. Biochem Pharmacol 2008;75(2):395-404
35. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzene sulfonamide (SC-58635, celecoxib). J Med Chem 1997;40(9):1347-65
36. Kusunoki N, Ito T, Sakurai N, et al. A celecoxib derivative potently inhibits proliferation of colon adenocarcinoma cells by induction of apoptosis. Anticancer Res 2006;26(5A):3229-36
37. Kusunoki N, Ito T, Sakurai N, et al. A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts. J Pharmacol Exp Ther 2005;314(2):796-803
38. Backhus LM, Petasis NA, Uddin J, et al. Dimethyl-celecoxib as a novel non-COX-2 therapy in the treatment of lung cancer. J Thorac Cardiovasc Surg 2005;130:1406-12
39. Kardosh A, Soriano N, Liu Y-T, et al. Multi-rarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2-inhibitory analog of celecoxib. Blood 2005;106:4330-8
40. Kardosh A, Soriano N, Pyrko P, et al. Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib. J Biomed Sci 2007;14(5):647-62
41. Song X, Lin HP, Johnson AJ, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94(8):585-91
42. Zhu J, Huang JW, Tseng PH, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004;64(12):4309-18
43. Kardosli A, Wang W, Uddin J, et al. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 2005;4(5):571-82
44. Lin HP, Kulp SK Tseng PH, et al. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther 2004;3(12):1671-80
45. Johnson AJ, Smith LL, Zhu J, et al. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL tells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 2005;105(6):2504-9
46. Kucab JE, Lee C, Chen CS, et al. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 2005;7(5):R796-807
47. Li J, Zhu J, Melvin WS, et al. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg 2006;10(2):207-14
48. Tong Z, Wu X, Chen CS, et al. Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells. Lung Cancer 2006;52(1):117-24
49. Yacoub A, Park MA, Hanna D, et al. OSU-03012 promotes caspase-independent but PERK-, cathepsin B, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006;70(2):589-603
50. Tseng PH, Lin HP, Zhu J, et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 2005;105(10):4021-7
51. Tseng PH, Wang YC, Weng SC, et al. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol 2006;70(5):1534-41
52. Ding H, Han C, Zhu J, et al. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 2005;113(5):803-10
53. To K, Zhao Y, Jiang H, et al. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmacol 2007; 72(3):641-52
54. Zhang S, Suvannasankha A, Crean CD, et al. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res 2007;13(16):4750-8
55. Sargeant AM, Klein RD, Rengel RC, et al. Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicol Pathol 2007;35(4):549-61
56. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-10
57. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62(3):625-31
58. Niederberger E, Manderscheid C, Grosch S, et al. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 2004;68(2):341-50
59. Arico S, Pattingre S, Bauvy C, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002;277(31):27613-21
60. Paulson SK, Engel L, Reitz B, et al. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 1999;27(10):1133-42
61. Buvanendran A, Kroin JS, Tuman KJ, et al. Cerebrospinal fluid and plasma pharmacokinetics of the cyclooxygenase 2 inhibitor rofecoxib in humans: single and multiple oral drug administration. Anesth Analg 2005;100(5):1320-4
62. Paulson SK, Zhang JY, Breau AP, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 2000;28(5):514-21
63. Paulson SK, Vaughn MB, Jessen SM, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 2001;297(2):638-45
64. Paulson SK, Hribar JD, Liu NW, et al. Metabolism and excretion of [(14)C] celecoxib in healthy male volunteers. Drug Metab Dispos 2000;28(3):308-14
65. Slaughter D, Takenaga N, Lu P, et al. Metabolism of rofecoxib in vitro using human liver subcellular fractions. Drug Metab Dispos 2003;31(11):1398-408
66. Dembo G, Park SB, Kharasch ED. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005;102(2):409-15
67. Kang SG, Kim JS, Park K, et al. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 2006;15(1):7-13
68. Nam DH, Park K, Park C, et al. Intracranial inhibition of glioma cell by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep 2004;11(2):263-8
69. Wang W, Kardosh A, Su YS, et al. Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model. Neurosurg Focus 2006;21(5):E14
70. Levin VA, Giglio P, Puduvalli VK, et al. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol 2006;78(1):85-90
71. Reardon DA, Quinn JA, Vredenburgh J, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005;103(2):329-38
72. Marnett LJ, Kalgutkar AS. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol Sci 1999;20(11):465-9
73. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87(5):803-9
74. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342(26):1946-52
75. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355(9):873-84
76. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352(11):1071-80
77. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092-102
78. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355(9):885-95
79. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006;6:27
80. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 2007;42:193-212
81. Cerchietti LC, Bonomi MR, Navigante AH, et al. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases J Neurooncol 2005;71(1):73-81
82. Crane CH, Mason K, Janjan NA, et al. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol 2003;26(4):S81-4
83. Gadgeel SM, Ruckdeschel JC, Heath EI, et al. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2(4):299-305
84. Gaffney DK, Winter K, Dicker AP, et al. A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys 2007;67(1):104-9
85. Gridelli C, Gallo C, Ceribelli A, et al. Factorial Phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 2007;8(6):500-12
86. Liao Z, Komaki R, Milas L, et al. A Phase I clinical trial of thoracic radiotherapy and concurrent celecoxib. for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 2005;11(9):3342-8
87. O'Byrne KJ, Danson S, Dunlop D, et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol 2007;25(22):3266-73
88. Smith MR, Manola J, Kaufman DS, et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006;24(18):2723-8
89. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343(21):1520-812 p following 8
90. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10):1247-55
91. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114(10):1028-35